Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy

Genetic and in vivo evidence suggests that aberrant recognition of RNA-containing autoantigens by Toll-like receptors (TLRs) 7 and 8 drives autoimmune diseases. Here we report on the preclinical characterization of MHV370, a selective oral TLR7/8 inhibitor. In vitro, MHV370 inhibits TLR7/8-dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawtin, Stuart, André, Cédric, Collignon-Zipfel, Géraldine, Appenzeller, Simone, Bannert, Bettina, Baumgartner, Lea, Beck, Damian, Betschart, Claudia, Boulay, Thomas, Brunner, Hermine I., Ceci, Melanie, Deane, Jonathan, Feifel, Roland, Ferrero, Enrico, Kyburz, Diego, Lafossas, Frederique, Loetscher, Pius, Merz-Stoeckle, Christina, Michellys, Pierre, Nuesslein-Hildesheim, Barbara, Raulf, Friedrich, Rush, James S., Ruzzante, Giulia, Stein, Thomas, Zaharevitz, Samantha, Wieczorek, Grazyna, Siegel, Richard, Gergely, Peter, Shisha, Tamas, Junt, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213863/
https://www.ncbi.nlm.nih.gov/pubmed/37196635
http://dx.doi.org/10.1016/j.xcrm.2023.101036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213863/
https://www.ncbi.nlm.nih.gov/pubmed/37196635
http://dx.doi.org/10.1016/j.xcrm.2023.101036

Ejemplares similares